489 Bevacizumab (BV) in combination with chemotherapy in the treatment of HER2-negative metastatic breast cancer (mBC): PFS subgroup results from two phase III studies
J. Glaspy, V. Dieras, A. Brufsky, D.W. Miles, S.C. Phan, J. O'ShaughnessyVolume:
8
Year:
2010
Language:
english
DOI:
10.1016/s1359-6349(10)70510-3
File:
PDF, 48 KB
english, 2010